BioProject

Analysis of bone marrow (BM) samples in multiple myeloma (MM) patients can lead to underestimation of the genetic heterogeneity within the tumor. More...

Analysis of bone marrow (BM) samples in multiple myeloma (MM) patients can lead to underestimation of the genetic heterogeneity within the tumor. Blood-derived liquid biopsies may provide a more comprehensive approach to genetic characterization. However, no thorough comparison between the currently available circulating biomarkers as tools for mutation profiling in MM has been published yet and the use of extracellular vesicle-derived DNA for this purpose in MM is not yet investigated. Therefore, we collected BM aspirates and blood samples in 30 patients with active MM to isolate five different DNA-types, i.e. cfDNA, EV-DNA, BM-DNA and DNA isolated from peripheral blood mononucleated cells (PBMNCs-DNA) and Circulating Tumor Cells (CTC-DNA). DNA was analyzed for genetic variants with targeted gene sequencing using a 165-gene panel. After data filtering, 87 somatic and 39 germline variants were detected among 149 sequenced DNA samples. cfDNA showed the highest concordance with the mutation profile observed in BM-DNA and outperformed EV-DNA, CTC-DNA and PBMNCs-DNA. Of note, 16% of all somatic variants were only detectable in circulating biomarkers. Based on our analysis, cfDNA is the preferable circulating biomarker for genetic characterization in MM and its combined use with BM-DNA allows comprehensive mutation profiling in MM. Less...